400 mg Capsule (sold per piece) [PRESCRIPTION REQURIED]
MOLNUPIRAVIR 400 mg Capsule (sold per piece) [PRESCRIPTION REQURIED]
Molnupiravir is currently being studied for the treatment of coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2 virus.
Only limited clinical trial information is available at this time to support the use of molnupiravir for the treatment of COVID-19. More information is needed to know how well molnupiravir will work for the treatment of COVID-19 and the possible adverse events from it.
Molnupiravir has not undergone the standard review to be approved by the FDA for use. However, the FDA has approved an Emergency Use Authorization (EUA) to allow certain adults to receive molnupiravir for treatment of COVID-19.
Place of Origin
200 mg to 800 mg every 12 hours for 5 days (10 doses total) or as directed by the physician.
Each LAGEVRIO capsule, for oral use, contains 200 mg of molnupiravir and the following inactive, ingredients: croscarmellose sodium, hydroxypropyl cellulose, magnesium stearate and, microcrystalline cellulose and purified water. The capsule shell is made of hypromellose, red iron, oxide and titanium dioxide. The capsule is printed with white ink made of butyl alcohol,, dehydrated alcohol, isopropyl alcohol, potassium hydroxide, propylene glycol, purified water,, shellac, strong ammonia solution and titanium dioxide.